Kiniksa Pharmaceuticals International, Plc · NASDAQ:KNSA

Kiniksa Pharmaceuticals International — Investor Presentation (February 2017)

13 slides from Kiniksa Pharmaceuticals International's investor presentation, February 2017

  1. Slide 1: Corporate Overview

    Relentless. Passionate. Focused.™ Corporate Overview

  2. Slide 2: Kiniksa Corporate Summary

    Kiniksa Corporate Summary 1 • Founded in 2015 by the former Synageva Incorporation executive management team after Synageva was acquired for $9.5b (incl. cash) 2 • $80m Series A from a Private Investment Financed Group and Management Team (prior to first asset) 3 Acquired KPL-716 • Applying strict c

  3. Slide 3: Kiniksa Senior Team

    Kiniksa Senior Team Sanj K. Patel Steve Carsten Chris John Greg Christine Thomas Rasmus Aaron Young Eben Tessari Mahoney Boess Heberlig Paolini Grabowski Maurer Beetham Jorgensen Chairman & Chief Chief Chief Chief Chief Program Chief Legal Strategy & Intellectual Business Chief Operating Business Fi

  4. Slide 4: Track record of fast execution from product concept to approval

    Track record of fast execution from product concept to approval Sanj K. Patel joins Synageva as CEO Under 5 years from IND to US & EU Approval 4

  5. Slide 5: Kiniksa Fundamentals

    Kiniksa Fundamentals Right Assets Right Capital Right Team 5

  6. Slide 6: Building a Generational Company

    Building a Generational Company Areas of Focus Core Capabilities Mission Devastating diseases with high unmet need Solving Execution Paving Disciplined complex from accelerated Potential for step-change in data-driven problems to discovery to path for therapy execution unlock value commercial produc

  7. Slide 7: Building Global Capabilities

    Building Global Capabilities  Business Development Genzyme/Synageva/Vertex  Discovery & Research Synageva/Cubist/Vertex  Clinical Development Genzyme/Synageva/Merck/Novartis/Bayer  Manufacturing Shire/Teva/Tessaro  Program management Synageva/Biogen  Quality GSK/GE Healthcare/Tessaro  Commerc

  8. Slide 8: Leveraging experience to go Bigger, Better, Faster

    Kiniksa – Leveraging experience to go Bigger, Better, Faster Every Second Counts! Patient Focus Compliance as an Asset Tightly Sequential Probabilistic Capital Allocation Early Financial & IP Planning Diversified Portfolio Data-Driven Decision-Making Foreign Parent Platform Global Commercialization

  9. Slide 9: Parallel Path Approach for Accelerated Build and Value Creation

    Parallel Path Approach for Accelerated Build and Value Creation Acquisition of assets Internal Discovery & Development Transformational transactions 9

  10. Slide 10: Right assets start with unmet patient need

    Right assets start with unmet patient need High Unmet Need Intellectual Clear Biology Property Early Signals Regulatory of Efficacy Pathway Reasonable Differentiating Sample Sizes Endpoints 10

  11. Slide 11: KPL-716: First-in-class mAb for devastating autoinflammatory and fibrotic conditions

    KPL-716: First-in-class mAb for devastating autoinflammatory and fibrotic conditions Inhibitor of two key • mAb inhibiting two cytokine pathways (inflammation and fibrosis) cytokine pathways • Proof of mechanism in a validated preclinical model • Acquired from established biopharma Robust preclinica

  12. Slide 12: Well Capitalized Capital Allocation

    Kiniksa Well Capitalized Capital Allocation Resources to deliver on programs Intelligent program gating Long Mindset Patient Focus Design-build Maximize value 12

  13. Slide 13: Relentless. Passionate. Focused.

    Relentless. Passionate. Focused.™ 13

Kiniksa Pharmaceuticals — Investor Presentation (February 2017) on 6ix